Zacks Investment Research on MSN2d
AXSM Settles Sunosi Patent Litigation With Hikma PharmaceuticalsAxsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...
2d
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...
Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...
3d
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...
Zacks Investment Research on MSN4d
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug FilingAxsome Therapeutics AXSM announced that it has received formal feedback from the FDA on its plans to seek approval for AXS-05 ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback